Medicare coverage for Alpha-1 Antitrypsin Deficiency Disorder treatment under Part B.

The John W. Walsh Alpha-1 Home Infusion Act of 2025 amends title XVIII of the Social Security Act to include coverage and payment for Alpha-1 Antitrypsin Deficiency Disorder treatment under Medicare Part B. This treatment includes augmentation therapy provided by qualified home infusion therapy suppliers in the individual's home. The bill specifies that payment will be made for intravenous administration kits and nursing services for up to 2 hours of care. The amendments will apply to items and services furnished on or after January 1, 2027.

Medicare coverage for Alpha-1 Antitrypsin Deficiency Disorder treatment under Part B.

The John W. Walsh Alpha-1 Home Infusion Act of 2025 amends title XVIII of the Social Security Act to include coverage and payment for Alpha-1 Antitrypsin Deficiency Disorder treatment under Medicare Part B. This treatment includes augmentation therapy provided by qualified home infusion therapy suppliers in the individual's home. The bill specifies that payment will be made for intravenous administration kits and nursing services for up to 2 hours of care. The amendments will apply to items and services furnished on or after January 1, 2027.